Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Stat Methods Med Res. 2021 Mar;30(3):717-730. doi: 10.1177/0962280220973697. Epub 2020 Nov 26.
Multi-arm multi-stage clinical trials in which more than two drugs are simultaneously investigated provide gains over separate single- or two-arm trials. In this paper we propose a generic Bayesian adaptive decision-theoretic design for multi-arm multi-stage clinical trials with () arms. The basic idea is that after each stage a decision about continuation of the trial and accrual of patients for an additional stage is made on the basis of the expected reduction in loss. For this purpose, we define a loss function that incorporates the patient accrual costs as well as costs associated with an incorrect decision at the end of the trial. An attractive feature of our loss function is that its estimation is computationally undemanding, also when >2. We evaluate the frequentist operating characteristics for settings with a binary outcome and multiple experimental arms. We consider both the situation with and without a control arm. In a simulation study, we show that our design increases the probability of making a correct decision at the end of the trial as compared to nonadaptive designs and adaptive two-stage designs.
多臂多阶段临床试验中同时研究两种以上药物提供了比单独的单臂或双臂试验更多的收益。本文提出了一种通用的贝叶斯自适应决策理论设计,用于具有 () 臂的多臂多阶段临床试验。基本思想是,在每一个阶段之后,根据预期的损失减少,基于预期的损失减少,对继续试验和为下一个阶段招募患者做出决定。为此,我们定义了一个损失函数,该函数将患者招募成本以及与试验结束时错误决策相关的成本纳入其中。我们的损失函数的一个吸引人的特点是,即使 >2,其估计的计算量也不大。我们评估了具有二项结果和多个实验臂的设置的频率操作特性。我们考虑了有无对照臂的情况。在一项模拟研究中,我们表明,与非自适应设计和自适应两阶段设计相比,我们的设计提高了在试验结束时做出正确决策的概率。